Study Type
Interventional - Device
completed
The objective of the VELETI II study was to evaluate the efficacy of stenting moderate SVG lesions with paclitaxel-eluting stents and/or PROMUS Element stent on reducing the first occurrence of the composite of cardiac death, myocardial infarction or repeat revascularization related to the target SVG over the duration of follow-up.
Primary Endpoint:
The first occurrence of the composite of cardiac death, myocardial infarction related to the target SVG or coronary revascularization related to the target SVG over the duration of the follow-up.
Jose Rodes-Cabau was the Principal Investigator.
Study Design
Randomized, prospective, multicenter
NO. of Countries
1
NO. of Sites
16
NO. of Participants
125
Study Period
2011-2016
Sponsor
PHRI
Sanjit Jolly
Scientist
Sanjit Jolly
Scientist
Sanjit Jolly is an interventional cardiologist at Hamilton Health Sciences and associate professor at McMaster University. He has formal training in clinical trials with a M.Sc. in Health Research Methodology from McMaster. He was the principal investigator of the RIVAL trial, a randomized trial of 7021 patients comparing radial and femoral access for coronary intervention. He is also the principal investigator trial of the ongoing TOTAL trial, an international randomized trial (N=10,700) of thrombectomy during primary PCI.
